An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer

Rafael Grochot; Christina Guo; Suzanne Carreira; Mateus Crespo; Jon Welti; Susana Miranda; Ines Figueiredo; Claudia Bertan; Jan Rekowski; Wei Yuan; Nina Tunariu; Katarzyna Abramowicz; Ana Ferreira; Ruth Riisnaes; Antje Neeb; Bora Gurel; Maria D. Fenor de la Maza; Khobe Chandran; Juliet Carmichael; Daniel Westaby; Hella Kohlhof; Adam L. Sharp; Alec Paschalis; Johann de Bono

doi:10.1016/j.euo.2026.02.014

Implication

Phase 1 study evaluates IMU-935's antitumour activity in patients with advanced prostate cancer, suggesting limited effectiveness.

Abstract

IMU-935 was well tolerated with no DLTs. One participant with MMRd mCRPC experienced a PSA response. Overall, however, robust antitumour activity was not observed in this molecularly unselected cohort.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Grochot et al. (2026) studied this question.

synapsesocial.com/papers/69b64c67b42794e3e660db23 https://doi.org/10.1016/j.euo.2026.02.014

View Full Paper

Ask AI

Bookmark

Share

An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer

Implication

Abstract

Discussion

Cite This Study

An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from European Urology Oncology

Keep reading

More related papers

More from European Urology Oncology